tremelimumab,durvalumab,Sorafenib,Atezolizumab,Bevacizumab
AstraZeneca,Pfizer,roche
['hcc']
do you stride or declare imbrave for 1st line tx of advanced #hcc ? dr. lau shows the 35% of patients who experienced immune-mediated aes with stride had 23mo os and more than 36% alive at 3 years. will this influence your decision making? #asco23 
Leader, GI Oncology @wilmotcancer. Researcher in #cachexia, #pancreaticcancer. Girl dad, @notredame alum, tweets opinion not medical advice